CEL-SCI(CVM)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.54 (+3.36%), 시가총액 $0.02B, 52주 범위 $1.19 ~ $13.04.
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the comp
CEL-SCI의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
CEL-SCI의 현재 주가는 $1.54 (+3.36%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
CEL-SCI의 시가총액은 약 $0.02B입니다.
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's l